Spark Therapeutics Inc. (NASDAQ:ONCE) insider Katherine A. High sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $60.37, for a total value of $603,700.00. Following the completion of the sale, the insider now owns 220,500 shares of the company’s stock, valued at $13,311,585. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) opened at 62.21 on Friday. The firm’s 50-day moving average is $59.11 and its 200 day moving average is $47.56. Spark Therapeutics Inc. has a 52 week low of $21.20 and a 52 week high of $66.00. The firm’s market capitalization is $1.90 billion.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Wednesday, August 10th. The company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $0.07. Spark Therapeutics had a negative net margin of 366.76% and a negative return on equity of 26.96%. The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $1.17 million. During the same period last year, the company earned ($0.60) earnings per share. Spark Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. Equities research analysts forecast that Spark Therapeutics Inc. will post ($3.96) EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in Spark Therapeutics by 10.6% in the second quarter. FMR LLC now owns 4,499,326 shares of the company’s stock valued at $230,051,000 after buying an additional 432,868 shares during the period. Vanguard Group Inc. boosted its stake in Spark Therapeutics by 28.9% in the second quarter. Vanguard Group Inc. now owns 1,512,600 shares of the company’s stock valued at $77,340,000 after buying an additional 338,720 shares during the period. JPMorgan Chase & Co. boosted its stake in Spark Therapeutics by 98.7% in the second quarter. JPMorgan Chase & Co. now owns 1,349,580 shares of the company’s stock valued at $69,003,000 after buying an additional 670,360 shares during the period. Lord Abbett & CO. LLC boosted its stake in Spark Therapeutics by 182.9% in the second quarter. Lord Abbett & CO. LLC now owns 1,165,207 shares of the company’s stock valued at $59,577,000 after buying an additional 753,377 shares during the period. Finally, BlackRock Fund Advisors boosted its stake in Spark Therapeutics by 34.3% in the second quarter. BlackRock Fund Advisors now owns 759,506 shares of the company’s stock valued at $38,834,000 after buying an additional 194,041 shares during the period. 78.79% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada assumed coverage on Spark Therapeutics in a research report on Tuesday, July 12th. They issued an “outperform” rating and a $70.00 target price for the company. Zacks Investment Research upgraded Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Thursday, August 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $94.00 price target on shares of Spark Therapeutics in a report on Thursday, August 11th. Jefferies Group reaffirmed a “hold” rating on shares of Spark Therapeutics in a report on Sunday, June 12th. Finally, Wedbush reaffirmed an “underperform” rating and issued a $29.00 price target on shares of Spark Therapeutics in a report on Monday, June 13th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $62.27.

About Spark Therapeutics

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.